AC
AI Cancer Cure
Evidence Atlas, updating nightly
Trials
Research
Support
Alternatives
Cancers
Biomarkers
Updates
Roadmap
Explore
← Back to trials
Trial not found
Could not find
NCT06325683
in the database yet.
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma | AI Cancer Cure